Daratumumab: a game changer in myeloma therapy

Affiliations

¹ Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, 1160 Vienna, Austria. Electronic address: heinz.ludwig@wienkav.at.

Comment

Heinz Ludwig. Lancet Haematol. 2020 Jun.

. 2020 Jun;7(6):e426-e427.

doi: 10.1016/S2352-3026(20)30105-8.

¹ Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, 1160 Vienna, Austria. Electronic address: heinz.ludwig@wienkav.at.

No abstract available

Comment on

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Usmani SZ, et al. Lancet Haematol. 2020 Jun;7(6):e447-e455. doi: 10.1016/S2352-3026(20)30081-8. Lancet Haematol. 2020. PMID: 32470437 Clinical Trial.